



US006716830B2

(12) **United States Patent**
Cagle et al.

(10) **Patent No.:** US 6,716,830 B2
(b4) **Date of Patent:** Apr. 6, 2004

- (54) **OPHTHALMIC ANTIBIOTIC COMPOSITIONS CONTAINING MOXIFLOXACIN**
- (75) Inventors: **Gerald Cagle**, Fort Worth, TX (US); **Robert L. Abshire**, Fort Worth, TX (US); **David W. Stroman**, Irving, TX (US); **John M. Yanni**, Burleson, TX (US)
- (73) Assignee: **Alcon, Inc.**, Hunenberg (CH)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: **10/200,868**
- (22) Filed: **Jul. 22, 2002**
- (65) **Prior Publication Data**
US 2002/0193370 A1 Dec. 19, 2002
- Related U.S. Application Data**
- (63) Continuation of application No. 09/646,797, filed as application No. PCT/US99/22622 on Sep. 29, 1999, now abandoned.
- (60) Provisional application No. 60/102,506, filed on Sep. 30, 1998, and provisional application No. 60/102,504, filed on Sep. 30, 1998.
- (51) **Int. Cl.** ⁷ **A61K 31/58; A61K 31/44**
- (52) **U.S. Cl.** **514/171; 514/230.2; 514/230.5; 514/300; 514/312; 514/913**
- (58) **Field of Search** **514/230.2, 230.5, 514/312, 300, 913, 171**

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,474,751 A	10/1984	Haslam et al.
4,551,456 A	11/1985	Katz
4,670,444 A	6/1987	Grohe et al.
4,710,495 A	12/1987	Bodor
4,730,013 A	3/1988	Bondi et al.
4,844,902 A	7/1989	Grohe
4,920,120 A	4/1990	Domagala et al.
4,980,470 A	12/1990	Masuzawa et al.
4,990,517 A	2/1991	Petersen et al.
4,996,335 A	2/1991	Bodor
5,059,597 A	10/1991	Petersen et al.
5,149,694 A	9/1992	Cagle et al.
5,164,402 A	11/1992	Brighty
5,185,337 A	2/1993	Fujii et al.
5,223,493 A	6/1993	Boltralik
5,416,096 A	5/1995	Petersen et al.
5,480,879 A	1/1996	Petersen et al.
5,540,930 A	7/1996	Guy et al.
5,563,138 A	10/1996	Ueda et al.
5,597,560 A	1/1997	Bergamini et al.
5,607,942 A	3/1997	Petersen et al.
5,631,004 A	5/1997	Cagle et al.
5,665,373 A	9/1997	Robertson et al.
5,679,665 A	10/1997	Bergamini et al.
5,849,752 A	12/1998	Grunenberg et al.
5,854,241 A	12/1998	Hallenbach et al.
5,912,255 A	6/1999	Bussell

FOREIGN PATENT DOCUMENTS

CA	2086914	7/1993
EP	0 982 031	3/2000
ES	08320	4/1993
WO	WO 90/01933	3/1990
WO	WO 96/39146	12/1996
WO	WO 98/06435	2/1998
WO	WO 99/15172	4/1999
WO	WO 00/18386	4/2000
WO	WO 00/18387	4/2000
WO	WO 00/18388	4/2000
WO	WO 00/18404	4/2000

OTHER PUBLICATIONS

- Blondeau, Joseph M., A review of the comparative in-vitro activities of 12 antimicrobial agents, with focus on five new 'respiratory quinolones', *Journal of Antimicrobial Chemotherapy*, vol. 43, Suppl. B, pp. 1-11 (1999).
- Elies, W., "Novel fluoroquinolones in the treatment of ENT infections", *Chemotherapie Journal*, 7/3, pp. 93-97 (1998) (no translation); XP000892813.
- Ernst et al., "Levofloxacin and trovafloxacin: The next generation of fluoroquinolones?", *Clinical Review, Am. J. Health-Syst. Pharm.*, vol. 54, pp. 2569-2584 (11/15/97).
- Gootz et al., "Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects", *Medicinal Research Reviews*, vol. 16, pp. 433-486 (1996).
- Kaw et al., "The penetration of trovafloxacin into the eye and CSF of rabbits", *IOVS*, vol. 40, no. 4, p. S88 (Mar. 15, 1999); XP-000892619.
- Kraseman et al., "Efficacy of Moxifloxacin against *Staphylococcus aureus* in respiratory tract and skin and skin structure infections", *Jurnal Of Antimicrobial Chemotherapy*, vol. 44, no. Suppl. A, pp 150 (7/99); XP000892776.
- McLeod et al., "The effect of topical trovafloxacin in a rabbit streptococcus pneumoniae keratitis model", *IOVS* vol. 40, no. 4, p. S689 (Mar. 15, 1999) XP-000892625.
- NCCLS Document M7-A4, "Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically", 4th Edition.
- "New Antimicrobial Agents Approved by the U.S. Food and Drug Administration in 1997 and New Indications for Previously Approved Agents" *Antimicrobial Agents and Chemotherapy*, vol. 42, No. 4, pp. 987-988 (Apr. 1, 1998); XP000872060.
- Ng et al., "Treatment of experimental staphylococcus epidermidis endophthalmitis with oral trovafloxacin" *American Journal of Ophthalmology*, vol. 216 (2), pp. 278-287 (Aug. 1998).

(List continued on next page.)

Primary Examiner—Zohreh Fay

(74) Attorney, Agent, or Firm—Gregg C. Brown

(57) **ABSTRACT**

Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.